Search results
Results from the WOW.Com Content Network
Radiation therapy is used to kill cancer cells; however, normal cells are also damaged in the process. Currently, therapeutic doses of radiation can be targeted to tumors with great accuracy using linear accelerators in radiation oncology; however, when irradiating using external beam radiotherapy, the beam will always need to travel through healthy tissue, and the normal liver tissue is very ...
TACE of liver tumors derives its beneficial effect by two primary mechanisms. [3] Most tumors within the liver are supplied by the proper hepatic artery, so arterial embolization preferentially interrupts the tumor's blood supply and stalls growth until neovascularization. Secondly, focused administration of chemotherapy allows for delivery of ...
Sirtex Medical Limited is a medical device firm that offers radioactive treatment for inoperable liver cancer called SIR-Spheres microspheres. [1] Sirtex was founded in 1997 in Australia and today has offices and production facilities in the U.S., Australia, Germany, and Singapore.
Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.
Merck said its drug met the main goal of significantly reducing the time to disease worsening, lung transplantation or death in a late-stage study of 172 patients with advanced stages of the ...
1990s – RFA for soft tissue tumors, i.e., bone, breast, kidney, lung and liver cancer. 1997 – Intra-arterial delivery of tumor-killing viruses and gene therapy vectors to the liver. 1997 – HIFU first used to treat prostate cancer. 2012 – Pioneering liver chemoperfusion study reported by Delcath for disseminated liver metastases. [32]
Selective internal radiation therapy (SIRT) can be used to destroy the tumor using selective injection of the artery or arteries supplying the tumor with a radioisotope agent. The agent is typically Yttrium-90 (Y-90) incorporated into embolic microspheres that lodge in the tumor vasculature, causing ischemia and delivering their radiation dose ...
"This is great news," Scott wrote on X. "As Senate Majority Leader, I will work with President Trump, (Elon Musk) and (Vivek Ramaswamy) to codify the Department of Government Efficiency ASAP."